At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 298 enrolled
Drug / intervention
Fingolimod +2 moredrug
Likely dose
Fingolimod 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT)
In Brief
A Phase 4 clinical trial evaluating Fingolimod, Interferon beta - 1a (IFN), and 1 other intervention for Relapsing Remitting Multiple Sclerosis. Completed, enrolled 298 participants across 26 sites.
Detailed Summary
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (fingolimod) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Remitting Multiple Sclerosis
CountriesRussia
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedFeb 2012
Primary CompletionJun 2013
TodayJul 2026
First PostedFeb 16, 2012
Enrollment StartJan 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.4 years ago
Interventions
Fingolimoddrug
0.5 mg orally once a day
Interferon beta - 1a (IFN)drug
44 mcg subcutaneously three times a week
Glatiramer acetate (GA)drug
20 mg subcutaneously once a day